Molecular and cellular basis of depigmentation in vitiligo patients

Abstract

Vitiligo is a chronic skin disease characterized by the appearance of zones of depigmentation. It is mostly described as an autoimmune disease in which the immune system destroys the melanocytes. Consistent with this origin, genetic studies have implicated genes encoding proteins mediating the immune response targeting melanocytes in the aetiology of this disease, together with proteins specific to these cells. However, the destruction of melanocytes by the immune system is neither global nor complete, because the patients do not display total depigmentation. The etiopathology of vitiligo is clearly complex and cannot be simply reduced to an autoimmune reaction directed against pigmented cells. Intrinsic changes have been observed in the melanocytes, keratinocytes and dermal cells of vitiligo patients. Identification of the molecular and cellular changes occurring in normally pigmented skin in vitiligo patients, and an understanding of these changes, is essential to improve the definition of trigger events for this disease, with a view to developing treatments with long‐term efficacy. This review focuses on the early events identified to date in the non‐lesional regions of the skin in vitiligo patients and discusses the process of repigmentation from melanocyte stem cells.

Mechanisms of melanocyte death in vitiligo

“…Keratinocyte numerically dominates the cell composition of the epidermis, it also interacts with melanocyte directly 71,72 . Cumulative research indicate that keratinocyte is not only an innocent bystander in melanocyte destruction, but a vital nexus in vitiligo pathomechanism.…”

Type-1 cytokines regulate matrix metalloprotease-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo

“…The stabilization of melanocytes in the basal layer of the epidermis is dependent on the adhesion protein E-cadherin (24,25). Interestingly, impaired cell-surface E-cadherin expression was recently shown in the nonlesional skin of patients with vitiligo (26,27). Several mechanisms could be involved in such a disruption, such as inhibition of its expression, internalization in the endosomal structure, or cell surface cleavage into a soluble form (soluble E-cadherin).…”

Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System

“…It is also noteworthy that eCB-dysregulation may also contribute to the development of vitiligo, a chronic skin disease characterized by localized or generalized de-pigmentation, having a rather complex, but chiefly autoimmune pathogenesis [162,163]. Indeed, similar to AA, the 1858 C/T missense single nucleotide polymorphism of PTPN22 (R620W; rs2476601) was shown to be associated with a higher vitiligo risk [164,165,166,167].…”